Table Of Contents
What is Xeljanz XR?
Xeljanz and Xeljanz XR (generic: tofacitinib) are prescription brand-name medications which the U.S. Food and Drug Administration (FDA) has approved to treat rheumatoid arthritis, psoriatic arthritis, and moderate to severe ulcerative colitis. Xeljanz XR is an extended-release (long-acting) form of the drug.
These tablets are long-acting because they release the medication slowly as they pass through your digestive system. Xeljanz XR tablets come in 11 mg and 22 mg strengths.
What’s the Problem With Xeljanz?
In 2019, the National Law Review reported on a surge of defective drug lawsuits filed over Xeljanz. The medicine, which works by suppressing a patient’s immune system, resulted in some users suffering a heightened risk of pulmonary embolisms and deep vein thrombosis (DVT).
Later that year, the FDA shared preliminary results from its study of Xeljanz highlighting data linking the drug to blood clotting problems. Specifically, the agency reported 19 cases of blood clots in the lungs in patients who received Xeljanz 10 mg twice daily compared to three cases in patients who received TNF blockers.
The agency further reported 45 patient deaths among people who took 10 mg of Xeljanz twice daily compared with 25 patient deaths for those who received TNF blockers.
- Xeljanz Lawsuit
- Xeljanz Lawyer & Side Effects Info
- Xeljanz Blood Clots Suit
- Xeljanz Class Action Litigation
See the other dangerous drug litigations our lawyers have covered.
Xeljanz Black Box Warning
As a result of the above findings, FDA required Pfizer to add a black box warning to its Xeljanz product labels, alerting patients and healthcare providers of the increased risk of blood clots and death with twice-daily doses of 10 mg each.
These risks most affected rheumatoid arthritis patients who were at least 50 years old and demonstrated at least one cardiovascular risk factor. Pfizer did not warn about blood clot risks prior to the placement of this black box warning, which was ultimately added in July 2019.
Xeljanz XR Side Effects
- Blood clots in the lungs
- Pulmonary embolism (PE)
- Deep vein thrombosis (DVT)
- Non-melanoma skin cancer
- Lung cancer
- Other cancers
- Heart attack
- Cardiovascular risk factor
- Major adverse cardiovascular event
- Ulcerative colitis
- Serious infections
- Immune system problems
- Extrapulmonary tuberculosis
- Invasive fungal infections
- Jaundice (yellowing of the eyes and/or skin)
- Breath chest pain
- Sudden shortness of breath
- Skin rash
- Other adverse events
What Compensation Could I Be Awarded in a Xeljanz Lawsuit?
The compensation you might recover for your Xeljanz injury will depend on the type and severity of your injury and the extent to which your injury has caused you to suffer physical, financial, and emotional damages.
When you hire our law firm to represent you in your pursuit of compensation, we will thoroughly research all the ways in which you have suffered a loss as a result of your injury. Depending on what our research uncovers, you could be eligible to recover any or all of the following types of damages:
- Past and future medical expenses
- Past and future pain and suffering that results from your injuries (both physical and mental)
- Wage loss
- Other economic losses
- Punitive damages
Get a Free Xeljanz XR Lawsuit Evaluation With Our Lawyers
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial attorneys that focus on the representation of plaintiffs in Xeljanz XR lawsuits. We are handling individual litigation nationwide and currently accepting new blood clot injury and death cases in all 50 states.
Free Xeljanz XR Lawsuit Evaluation: Again, if you were harmed after taking Xeljanz to treat rheumatoid arthritis, you should contact our attorneys immediately. Xeljanz XR patients may be entitled to a settlement for medical expenses by filing a Xeljanz XR lawsuit and our Xeljanz Attorneys can help.